Grundy, S

Jonsdottir, L

Roblin, K

Sarazin, V

Sternthal, S

Retrovirology

English

PubMed

V Sarazin

L Jonsdottir

S Sternthal

K Roblin

S Grundy

Springer - Publisher Connector

P15-20. Developing a national policy agenda for the Canadian HIV vaccine initiative

Crossref

BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessPoster presentation
P15-20. Developing a national policy agenda for the Canadian HIV 
vaccine initiative
V Sarazin*1, L Jonsdottir1, S Sternthal1, K Roblin2 and S Grundy2
Address: 1Public Health Agency of Canada, Office of HIV Vaccines, Ottawa, Canada and 2TDV Global Inc., Winnipeg, Canada
* Corresponding author    
Background
The Canadian HIV Vaccine Initiative (CHVI) is a five-year
initiative between the Government of Canada and the Bill
& Melinda Gates Foundation, and it represents a signifi-
cant Canadian contribution to the Global HIV Vaccine
Enterprise that seeks to accelerate the development of safe,
effective, affordable and globally accessible HIV vaccines.
A national HIV vaccines policy agenda is currently being
developed as one measure to contribute to domestic and
international HIV vaccines policy-related efforts.
Methods
To ensure alignment with global HIV vaccines efforts, a
consultation process with international experts was
undertaken in fall 2008 – winter 2009 to seek input on
key policy issues and potential areas of focus for a Cana-
dian HIV vaccines policy agenda.
Results
The consultations identified several key policy issues that
need to be resolved domestically and globally on the pol-
icy front. These include: focussing on the science to
develop an effective vaccine; assist low- and middle-
income countries in developing regulatory systems and
processes to enable approval and implementation of clin-
ical trials, and; positioning HIV vaccines as part of a com-
prehensive prevention approach. The consultations also
identified areas of focus for the CHVI policy agenda: share
Canada's unique approach to HIV prevention; initiate and
supporting ongoing global policy dialogue; engage global
partners to raise profile of HIV/AIDS issues, and; provide
support to global approaches to address regulatory barri-
ers in HIV vaccine development and delivery.
Conclusion
The consultation process was very valuable in identifying
current global policy issues and proposed areas for inclu-
sion in a CHVI Policy Agenda. The consultations also
demonstrated the interest and support for a more formal-
ized global policy network under the leadership of the
Global HIV Vaccine Enterprise. Canada is well positioned
to develop a sound policy agenda, one that will contribute
to both domestic and global goals to advance the develop-
ment of an HIV vaccine.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P221 doi:10.1186/1742-4690-6-S3-P221
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P221
© 2009 Sarazin et al; licensee BioMed Central Ltd. 


https://retrovirology.biomedcentral.com/track/pdf/10.1186/1742-4690-6-S3-P221?site=retrovirology.biomedcentral.com

P15-20. Developing a national policy agenda for the Canadian HIV vaccine initiative

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Crossref